pharmaceuticals Pharmaceuticals Pharmaceuticals Pharmaceuticals 1424-8247 Molecular Diversity Preservation International 10.3390/ph2030228 pharmaceuticals-02-00228 Article Malaria-Infected Mice Are Cured by a Single Low Dose of a New Silylamide Trioxane Plus Mefloquine Woodard Lauren E. 1 Mott Bryan T. 1 Singhal Vandana 2 Kumar Nirbhay 2 Shapiro Theresa A. 2 3 Posner Gary H. 1 2 * Department of Chemistry, School of Arts and Sciences, The Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218-2685, MD, USA; Email: lwoodar1@jhu.edu (L.E.W.); bmott2@jhu.edu (B.T.M.) Department of Molecular Microbiology and Immunology, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD Baltimore, MD 21205, USA; Email: vsinghal@jhsph.edu (V.S.); nkumar@jhsph.edu (N.K.) Division of Clinical Pharmacology, Department of Medicine, School of Medicine, The Johns Hopkins University, Baltimore, MD 21205, USA; Email: tshapiro@jhmi.edu (T.A.S.) Author to whom correspondence should be addressed; Email: ghp@jhu.edu. 21 12 2009 2009 2 3 228 235 24 11 2009 08 12 2009 18 12 2009 © 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 2009

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

Three thermally and hydrolytically stable silylamide trioxanes have been prepared from the natural trioxane artemisinin in only five simple chemical steps and in at least 56% overall yield. Two of these new chemical entities completely cured malaria-infected mice at a single oral dose of only 8 mg/kg combined with 24 mg/kg of mefloquine hydrochloride. The high efficacy of this ACT chemotherapy is considerably better than the efficacy using the popular trioxane drug artemether plus mefloquine hydrochloride.

 silylamide trioxanes antimalarial monomers and dimmers single dose oral cure 1. Introduction

Malaria is one of the world’s most widespread infectious diseases [1]. Much effort is currently being devoted to develop effective vaccines to prevent people from becoming infected with malaria parasites [2,3]. Chemotherapy of people having malaria using such antimalarial amines as chloroquine has been effective for over 50 years [1]. The increasingly widespread resistance of malaria parasites to chloroquine and related antimalarial amines [4], however, has stimulated a search for new natural and synthetic antimalarials.

Progress in chemotherapy has been made using protease inhibitors to starve the parasites [5,6], using antimalarial acridones [7] and new 4-aminoquinolines [8] to counteract resistance, and using some modified chloroquine analogs [9]. Trioxanes derived from artemisinin (1), such as artemether (2c) and sodium artesunate (2d), are now being used clinically to cure malaria-infected people [10,11,12,13,14,15,16]. The World Health Organization (WHO) has recommended that a combination of a trioxane plus an established amino antimalarial should be used chemotherapeutically [17]. Artemisinin combination therapy (ACT) usually involves 3-6 doses of a trioxane plus an amino antimalarial administered to a malaria-infected patient over several days [18,19,20,21,22]. Patient compliance would be improved and cost lowered by a single dose oral cure. Toward this important medical goal, we have reported cure of malaria-infected mice by a single subcutaneous dose of a trioxane dimer [23], a related series of trioxane dimers curative after three oral doses [24], a trioxane dimer sulfone plus mefloquine curative after only a single oral dose [25], a fluorinated amide trioxane monomer plus mefloquine curative after only a single oral dose [26], and also a 5-carbon-linked trioxane dimer plus mefloquine curative after only a single oral dose [27].

First Generation Semi-Synthetic Derivatives of Artemisinin.

Only recently has the beneficial effect of introducing a silicon atom in place of a carbon atom in some clinically used drugs begun to be appreciated [28]. This new appreciation inspired us to synthesize some silicon-containing trioxanes and to determine their antimalarial efficacy in rodents.

We report here an easily synthesized, new family of silylamide trioxane monomers 4 and dimer 6 (Scheme 1) able to cure malaria-infected mice after only a single 8 mg/kg oral dose combined with 24 mg/kg of mefloquine hydrochloride.

2. Results and Discussion 2.1. Chemistry

Chemical synthesis of new silylamide trioxane monomers 4a and 4b and silylamide trioxane dimer 6 from the natural artemisinin (1) proceeded easily on gram scale in at least 56% overall yield via dihydroartemisinin acetate (2b) and then via either trioxane monomer carboxylic acid 3 or trioxane dimer carboxylic acid 5 (Scheme 1). Quantitative amide formation was achieved using commercial silylamines and standard coupling reagents. Scale up to kilogram quantities is expected to be straightforward. Silylamide trioxanes 4a, 4b, and 6 are stable in the absence of solvent for at least 7 days at 60 °C and at least 1 day at 70 °C; less than 2% decomposition was observed by proton NMR spectroscopy. Because these silylamides are C-10 non-acetal trioxanes, they are more hydrolytically stable than the clinically used C-10 acetal trioxane drugs 2c and 2d.

pharmaceuticals-02-00228-f002_Scheme 1

Monomer and Dimer Silylamide Derivatives of Artemisinin.

 2.2. Biology

Each trioxane silylamide 4a, 4b, and 6 (0.90 mg) was dissolved in 0.11 mL of 7:3 Tween 80:ethanol and then diluted with 1.10 mL of water for oral administration to 5-week old C57BL/6J male mice (from the Jackson Laboratory) weighing 18-19 grams that were infected intraperitoneally on day 0 with the Plasmodium berghei, ANKA strain (2 × 107 parasitized erythrocytes) [26]. Each of 3 mice in a group was treated orally 24 hours post-infection with a single dose of 0.20 mL (0.20 mL/1.21 mL × 0.9 mg = 0.15 mg) of diluted compound solution, corresponding to a dose of 8 mg/kg, combined with 24 mg/kg of mefloquine hydrochloride. Determining blood parasitemia levels as well as monitoring the duration of animal survival compared to survival time of animals receiving no drug are both widely accepted as measures of a drug’s efficacy in antimalarial drug development. Three days after infection, an average of 7% blood parasitemia was observed in the control (infected but no drug) group. Animals infected but receiving no drug died on an average of 15 days post infection. A widely accepted yardstick of cure (i.e., 100% efficacy) is survival of animals to at least day 30 post infection, with no detectable malaria parasites in the animal’s blood at that time. Average survival results through day 57 (when the experiment was stopped) are summarized in Table 1.

pharmaceuticals-02-00228-t001_Table 1

Antimalarial Efficacy Using a Single Oral Dose of Trioxane (8 mg/kg) Combined with Mefloquine Hydrochloride (24 mg/kg) in Plasmodium berghei-infeced Mice.

Trioxane Average Survival (days) after Infection % Suppression of Parasitemia (on day 3 post infection)
2c 23 > 99.5
4a > 57 > 99.5
4b 44a > 99.5
6 > 57 > 99.5

a One mouse died on day 17; the other two mice in this group showed no parasitemia on day 57.

It is clear from Table 1 that both silylamides 4a and 6 administered as a single oral dose of 8 mg/kg plus mefloquine hydrochloride (24 mg/kg) cured the malaria-infected mice; on day 57 (when the experiment was terminated), no parasites were detected in the blood of the surviving mice. At a single oral dose of 22 mg/kg, mefloquine hydrochloride alone was not curative. In an ACT control experiment, the popular trioxane drug artemether (2c) combined with mefloquine hydrochloride prolonged mouse average survival until only day 23 (Table 1). Neither overt toxicity nor behavioral change attributable to trioxane drug administration was observed in any of the malaria-infected animals cured by trioxane 4a or 6 plus mefloquine hydrochloride combination. By the end of the experiment, all the mice receiving the silylamides 4a and 6 had gained as much weight (8–10 g) as had the mice in an uninfected control group: this weight gain result is a strong indication of the apparent safety of these silylamides under conditions in which they are curative.

 3. Experimental

High-pressure liquid chromatography (HPLC) was performed on a Rainin HPLX system equipped with two 25-mL pump heads and a Rainin Dynamax UV-C dualbeam variable wavelength detector set at 254 using a Phenomenex Luna 5 μ C18 250 × 10 mm column. The purity of analogs 4a, 4b, and 6 was ≥ 98% based on HPLC analysis. Nuclear magnetic resonance spectra were recorded on a Bruker 400 MHz spectrometer with chloroform as the reference. Infrared spectra were obtained using a Perkin-Elmer Series FT-IR instrument. Optical rotation measurements were taken on a Jasco P-1010 polarimeter. Mass spectroscopy data were obtained using a VG-70S magnetic sector mass spectrometer.

Synthesis of monomer LW-ART-EtC(O)-NHCH2SiMe3 (4a). Monomer acid ART-EtC(O)-OH (3 [26], 0.60 g, 1.8 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 0.55 g, 2.9 mmol), and hydroxybenzotriazole (HOBt, 0.30 g, 2.2 mmol) were charged into a flame-dried 100 mL round bottom flask at room temperature. Dichloromethane (37 mL) was then added and the mixture was stirred for an hour at which time, (trimethylsilyl)methylamine (0.48 mL, 3.6 mmol) was added by syringe. The reaction was allowed to stir at room temperature for 3 hours. It was then quenched with 1N HCl, extracted with dichloromethane (3 × 5 mL), washed with brine, dried over magnesium sulfate and evaporated. The crude product was purified by preparative thin layer chromatography (silica gel, 40% EtOAc/Hexanes) to afford LW-ART-EtC(O)-NHCH2SiMe3 (4a) as an amorphous, white solid (0.72 g, 1.7 mmol, 94%): IR (thin film) 3295, 2951, 2876, 1743, 1637, 1547, 1451, 1376, 1279, 1249, 1189, 1126, 1094, 1057, 1011, 946, 911, 853 cm-1; 1H-NMR (400 MHz, CDCl3) δ 5.67 (br. s, 1H), 5.26 (s, 1H), 4.04 (m, 1H), 2.74-2.66 (m, 3H), 2.44 (m, 1H), 2.33-2.21 (m, 2H), 2.01-1.74 (m, 5H), 1.63-1.51 (m, 2H), 1.46-1.17 (m, 7H, including singlet at 1.36), 0.95-0.91 (m, 4H), 0.84 (d, 3H, J=7.6 Hz), 0.03 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 173.20, 103.36, 88.74, 81.13, 75.98, 52.42, 44.45, 37.38, 36.50, 34.55, 34.43, 30.14, 29.78, 26.17, 25.26, 24.85, 24.63, 20.20, 13.15, -2.63; [α]D23= +61 (c=0.23, CHCl3); HRMS (FAB) m/z calcd for C22H39NO5Si (M)+ 425.2598, found 425.2584.

Synthesis of monomer LW-ART-EtC(O)-NH(CH2)3SiMe3 (4b). Monomer acid ART-EtC(O)-OH (3 [26], 30 mg, 0.088 mmol), EDC (27 mg, 0.14 mmol), and HOBt (15 mg, 0.11 mmol) were charged into a flame-dried 5 mL round bottom flask at room temperature. Dichloromethane (2.5 mL) was then added and the mixture was stirred for an hour at which time, 3-aminopropyltrimethylsilane (24 mg, 0.18 mmol) was added by syringe. The reaction was allowed to stir at room temperature for 3 hours. It was then quenched with 1N HCl, extracted with dichloromethane (3 × 5 mL), washed with brine, dried over magnesium sulfate and evaporated. The crude product was purified by preparative thin layer chromatography (silica gel, 40% EtOAc/Hexanes) to afford LW-ART-EtC(O)-NH(CH2)3SiMe3 (4b) as an amorphous, white solid (42 mg, 0.088 mmol, 100%): IR (thin film) 3304, 2951, 2875, 1644, 1547, 1452, 1376, 1248, 1222, 1188, 1126, 1096, 1057, 1012, 938, 912, 862, 837, 753 cm-1; 1H-NMR (400 MHz, CDCl3) δ 5.82 (br. s, 1H), 5.27 (s, 1H), 4.03 (m, 1H), 3.18 (m, 2H), 2.70 (m, 1H), 2.46-2.39 (m, 1H), 2.34-2.21 (m, 2H), 2.01-1.76 (m, 5H), 1.64-1.18 (m, 11H, including singlet at 1.37), 0.95-0.92 (m, 4H), 0.85 (d, 3H, J=7.6 Hz), 0.45 (m, 2H), -0.04 (s, 9H); 13C-NMR (100 MHz, CDCl3) δ 172.91, 103.37, 88.71, 81.16, 76.10, 52.43, 44.47, 42.72, 37.39, 36.52, 34.72, 34.44, 30.17, 26.17, 25.02, 24.86, 24.64, 24.17, 20.21, 13.84, 13.19, -1.76; [α]D23= +64 (c=0.24, CHCl3); HRMS (FAB) m/z calcd for C24H44NO5Si (M+H)+ 454.2989, found 454.2980.

Synthesis of dimer BTM-isobu-C(O)NHCH2SiMe3 (6). Carboxylic acid dimer 5 (15 mg, 0.03 mmol), EDC (4.4 mg, 0.03 mmol, 1.1 eq) and HOBt (3.8 mg, 0.03 mmol, 1.1 eq) were charged into a flame-dried 5 mL round bottom flask at room temperature. Dichloromethane (1 mL) and (trimethylsilyl)methylamine (4 mL, 0.03 mmol, 1.1 eq) were added, and the reaction mixture was stirred at rt for 2 hours. The reaction mixture was further diluted with CH2Cl2, and the organic layer was washed with water and sat. aq. NaCl, extracted, dried on MgSO4, filtered, and the solvent was removed under reduced pressure. The residue was purified directly on silica. Isocratic elution (25% ethyl acetate in hexanes) afforded the desired product as an amorphous, colorless solid: (17.8 mg, 0.03mmol, 100%): IR (thin film) 3315, 2950, 2875, 1716, 1647, 1540, 1456, 1375, 1249, 1205, 1124, 1093, 1052, 1011, 939, 856; 1H-NMR (400 MHz, CDCl3) d 5.97 (t, 1 H, J = 5.08 Hz), 5.26 (s, 1 H), 5.24 (s, 1 H), 4.09 (m, 1 H), 3.98 (m, 1 H), 2.82 (dd, 1 H, J = 5.94, 15.28), 2.72 (sextet, 2 H, J = 6.67), 2.66 (dd, 1 H, J = 5.05, 15.16), 2.58 (m, 1 H), 2.32 (td, 2 H, J = 3.71, 13.96), 2.05 (m, 4 H), 1.86 (m, 4 H), 1.74 (m, 4 H), 1.63 (m, 6 H), 1.51 (m, 6 H), 1.39 (m, 9 H, including singlets at 1.40 and 1.37), 1.25 (m, 6 H), 0.94 (m, 6 H), 0.84 (m, 4 H), 0.07 (s, 9 H); 13C-NMR (100 MHz, CDCl3) d175.87, 103.46,103.44, 101.08, 88.38, 88.29, 81.19, 81.01, 75.87, 74.26, 52.56, 52.54, 44.76, 44.69, 37.33, 37.26, 36.62, 36.51, 34.51, 29.79, 29.77, 29.71, 26.19, 26.11, 24.73, 24.66, 24.59, 24.56, 20.22, 13.24, -2.42; [a]D23=+59 (c=0.69, CHCl3); HRMS (FAB) m/z calcd for C38H63NO9Si (M+H) 706.4348, found 706.4350.

 4. Conclusions

In conclusion, a single-digit oral dose of trioxane monomer silylamide 4a or of trioxane dimer silylamide 6, combined with mefloquine hydrochloride, is considerably more antimalarially efficacious than the popular ACT trioxane drug artemether (2c) combined with mefloquine hydrochloride [17,29,30,31,32]. Complete cure of malaria-infected mice was achieved with silylamides 4a and 6, which appear to be safe at the curative dose. Preclinical drug development is continuing, including trioxane lead optimization and use of other amine combination partners.

 Acknowledgments

We thank the NIH (AI 34885 to GHP), the Johns Hopkins Malaria Research Institute and the Bloomberg Family Foundation for financial support (to GHP and to NK).

 References Ridley R.G. Medical Need, Scientific Opportunity, and the Drive for Antimalarial Drugs Nature 2002 415 686 693 10.1038/415686a11832957 LeBlanc R. Vasquez Y. Hannaman D. Kumar N. Markedly Enhanced Immunogenicity of a Pfs25 DNA Based Malaria Transmission Blocking Vaccine by in Vivo Electroporation Vaccine 2008 26 185 192 18054817 Troye-Blomberg M. Berzins K. Rational Vaccine Development against Malaria Microbes Infect. 2007 9 749 750 10.1016/j.micinf.2007.02.005 Olliaro P.L. Boland P.B. Clinical Public Health Implications of Antimalarial Drug Resistance Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovry Rosenthal P.J. Humana Press Totowa, NJ, USA 2002 65 83 Hof F. Schütz A. Fäh C. Meyer S. Bur D. Liu J. Goldberg D.E. Diederich F. Starving the Malaria Parasite: Inhibitors Active Against the Aspartic Proteases Plasmepsins I, II, and IV Angew. Chem. Int. Ed. 2006 45 2138 2141 10.1002/anie.200504119 Pandey K.C. Sijwall P.S. Singh A. Na B.-K. Rosenthal P.J. Independent Intramolecular Mediators of Folding, Activity, and Inhibition for the Plasmodium falciparum Cysteine Protease Falcipain-2 J. Biol. Chem. 2004 279 3484 3491 14625277 Kelly J.X. Smilkstein M.J. Brun R. Wittlin S. Cooper R.A. Lane K.D. Janowsky A. Johnson R.A. Dodean R.A. Winter R. Hinrichs D.J. Riscoe M.K. Discovery of dual function acridones as a new antimalarial chemotype Nature 2009 459 270 273 10.1038/nature0793719357645 Yearick K. Ekoue-Kovi K. Iwaniuk D.P. Natarajan J.K. Alumasa J. de Dios A.C. Roepe P.D. Wolf C. Overcoming Drug Resistance to Heme-targeted Antimalarials by Systematic Side Chain Variation of 7-Chloro-4-aminoquinolines J. Med. Chem. 2008 51 1995 1998 10.1021/jm800106u18345611 Ramanathan-Girish S. Catz P. Creek M.R. Wu B. Thomas D. Krogstad D.J. De D Mirsalis J.C. Green C.E. Pharmacokinetics of the Antimalarial Drug, AQ-13, in Rats and Cynomolgus Macaques Int. J. Toxicol. 2004 23 179 189 15204721 Klayman D.L. Qinghaosu (Artemisinin): An Antimalarial Drug from China Science 1985 228 1049 1055 10.1126/science.38875713887571 O’Neill P.M. Posner G.H. A Medicinal Chemistry Perspective on Artemisinin and Related Endoperoxides J. Med. Chem. 2004 47 2945 2964 10.1021/jm030571c15163175 Tang Y. Dong Y. Vennerstrom J.L. Synthetic Peroxides as Antimalarials Med. Res. Rev. 2004 24 425 448 10.1002/med.1006615170591 Jefford C.W. Synthetic Peroxides as Antimalarials Curr. Opin. Vest. Drugs (Thomson Sci.) 2004 5 866 872 Haynes R.K. From Artemisinin to New Artemisinin Antimalarials: Biosynthesis, Extraction, Old and New Derivatives, Stereochemistry and Medicinal Chemistry Requirements Curr. Top. Med. Chem. 2006 6 509 537 16719805 10.2174/156802606776743129 Bégué J.-P. Bonnet-Delpon D. Fluoroartemisinins: Metabolically More Stable Antimalarial Artemisinin Derivatives ChemMedChem 2007 2 608 624 10.1002/cmdc.20060015617252616 Gelb M.H. Drug discovery for malaria: A very challenging endeavor Curr. Opin. Chem. Biol. 2007 11 440 445 10.1016/j.cbpa.2007.05.03817761335 World Health Organization Guidelines for the Treatment of Malaria WHO Geneva, Switzerland 2006 Ashley E.A. White N.J. Artemisinin-based combinations Curr. Opin. Infect. Dis. 2005 18 531 536 10.1097/01.qco.0000186848.46417.6c16258328 Adjuik M. Babiker A. Garner P. Olliaro P. Taylor W. White N. Artesunate combinations for treatment of malaria: meta-analysis Lancet 2004 363 9 17 10.1016/S0140-6736(03)15162-814723987 Guthmann J.-P. Cohuet S. Rigutto C. Fortes F. Saraiva N. Kiguli J. Kyomuhendo J. Francis M. Noel F. Mulemba M. Balkan S. High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola Am. J. Trop. Med. Hyg. 2006 75 143 145 16837721 Myint H.Y. Ashley E.A. Day N.P.J. Nosten F. White N.J. Efficacy and safety of dihydroartemisinin-piperaquine Trans. R. Soc. Trop. Med. Hyg. 2007 101 858 866 10.1016/j.trstmh.2007.05.01817659311 Fanello C.I. Karema C. van Doren W. Van Overmeir C. Ngamije D. D’Alessandro U. A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem®) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda Trans. R. Soc. Trop. Med. Hyg. 2007 101 344 350 17005222 10.1016/j.trstmh.2006.06.010 Posner G.H. Paik I.-H. Chang W. Borstnik K. Sinishtaj S. Rosenthal A.S. Shapiro T.A. Malaria-infected mice are cured by a single dose of novel artemisinin derivatives J. Med. Chem. 2007 50 2516 2519 10.1021/jm070149m17439113 Posner G.H. Chang W. Hess L. Woodard L. Sinishtaj S. Usera A.R. Maio W. Rosenthal A.S. Kalinda A.S. D’Angelo J.G. Petersen K.S. Stohler R. Chollet J. Santo-Tomas J. Snyder C. Rottmann M. Wittlin S. Brun R. Shapiro T.A. Malaria-infected mice are cured by oral administration of new artemisinin derivatives J. Med. Chem. 2008 51 1035 1042 10.1021/jm701168h18232653 Rosenthal A.S. Chen X. Liu J.O. West D.C. Hergenrother P.J. Shapiro T.A. Posner G.H. Malaria-Infected Mice Are Cured by a Single Oral Dose of New Dimeric Trioxane Sulfones Which Are Also Selectively and Powerfully Cytotoxic to Cancer Cells J. Med. Chem. 2009 52 1198 1203 10.1021/jm801484v19186946 Woodard L.E. Chang W. Chem X. Liu J.O. Shapiro T.A. Posner G.H. Malaria-Infected Mice Live until at Least Day 30 after a New Monomeric Trioxane Combined with Mefloquine are Administered Together in a Single Low Dose J. Med. Chem. 2009 52 in press 10.1021/jm801484v19186946 Moon D.K. Singhal V. Kumar N. Shapiro T.A. Posner G.H. Antimalarial Preclinical Drug Development: A Single Oral Dose of A 5-Carbon-linked Trioxane Dimer Plus Mefloquine Cures Malaria-Infected Mice Drug Dev. Res. 2009 in press Gately S. West R. Novel Therapeutics With Enhanced Biological Activity Generated by the Strategic Introduction of Silicon Isosteres into Known Drug Scaffolds Drug Dev. Res. 2007 68 156 163 10.1002/ddr.20177 Sagara I. Rulisa S. Mbacham W. Adam I. Sissoko K. Maiga H. Traore O.B. Dara N. Dicko Y.T. Dicko A. Djimde A. Jansen F.H. Doumbo O.K. Efficacy and Safety of a Fixed Dose Artesunate-sulphamethoxypyrazine-pyrimethamine Compared to Artemether-lumefantrine for the Treatment of Uncomplicated falciparum malaria across Africa: A Randomized Multi-centre trial Malaria J. 2009 8 63 10.1186/1475-2875-8-63 Gautam A. Ahmed T. Batra V. Paliwal J. Pharmacokinetics and Pharmacodynamics of Endoperoxide Antimalarials Curr. Drug. Metab. 2009 10 289 306 10.2174/13892000978784632319442090 Arinaitwe E. Sandison T.G. Wanzira H. Kakuru A. Homsy J. Kalamya J. Kamya M.R. Vora N. Greenhouse B. Rosenthal P.J. Tappero J. Dorsey G. Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Falciparum Malaria: A Longitudinal, Randomized Trial in Young Ugandan Children Clin. Infect. Dis. 2009 49 1629 1637 10.1086/64794619877969 Eastman R.T. Fidock D.A. Artemisinin-based Combination Therapies: A Vital Tool in Efforts to Eliminate Malaria Nat. Rev. Micro. 2009 7 864 874